Loading stock data…
EW
$83.98+0.48 (+0.57%)
Market ClosedLast close May 1
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Edwards Lifesciences Corporation in the Healthcare sector is trading at $83.98. The stock is currently 4% below its 52-week high of $87.89, remaining 3.6% above its 200-day moving average. Technical signals show neutral RSI of 66 and bullish MACD crossover, explaining why EW maintains its current momentum and trend strength. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 66) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$83.98
Potential Downside
42.2%
Whystock Fair Value$48.51
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus27 analysts
Buy
Mean target$97.15+15.7%
Range$84.00 – $110.00
Fundamentals
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive re...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$47.35B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
45.04
Beta
Defensive asset. Lower volatility than the S&P 500.
0.94
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
40.10%
Volume
Today's trading volume
6.11M
Recent News
Global's Undervalued Small Caps With Insider Actions For May 2026
As global markets navigate a complex landscape marked by record highs in major U.S. stock indexes, driven by robust economic data and AI-linked stocks, small-cap companies are capturing investor interest amid resilient consumer demand and evolving geopolitical tensions. In this environment, identifying promising small-cap stocks involves considering factors such as strong earnings potential and strategic insider actions that align with broader market trends.
Barclays Lifts PT on Edwards Lifesciences Corporation (EW) Following Q1 Earnings
Edwards Lifesciences Corporation (NYSE:EW) is one of the best medical device stocks to invest in right now. Barclays raised the price target on Edwards Lifesciences Corporation (NYSE:EW) to $110 from $104 on April 27, reaffirming an Overweight rating on the shares. The rating update came after the company’s fiscal Q1 earnings, with the firm telling […]
How The Edwards Lifesciences (EW) Investment Story Is Shifting As Views On Growth Diverge
Edwards Lifesciences just saw its modeled fair value edge from US$96.93 to US$96.96, a tiny move that still reflects fresh thinking about where the shares might reasonably trade. That small adjustment comes as research houses pull in different directions, with some lifting price targets by US$1 to US$6 and others trimming them by as much as US$13, all circling around questions of execution, growth, and risk. As you read on, you will see how to interpret these shifting targets and keep up with...
EW's Q1 Earnings Beat, Revenues Match, '26 View Up, Stock Climbs
Edwards Lifesciences beats on Q1 earnings, matches revenue estimates, lifts 2026 outlook as TAVR and TMTT growth accelerates; shares rise on stronger guidance and margin expansion.
Edwards Lifesciences raises FY26 guidance following strong Q1
Edwards Lifesciences revealed that its Q1 2026 performance was better than expected, prompting it to uplift its previous FY26 outlook.